Cytokinetics Inc. has disclosed fast type myosin-binding protein C (MYBPC2) inhibitors reported to be useful for the treatment of neuromuscular disorders.

Humanwell Pharmaceutical US Inc. has described sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain, arrhythmia, cough, urinary incontinence and multiple sclerosis.

Hanmi Holdings Co. Ltd. has divulged heterocyclic derivatives acting as inhibitors of eukaryotic translation initiation factor 2-α kinase 4 (GCN2), eukaryotic translation initiation factor 2-α kinase 1 (HRI), eukaryotic translation initiation factor 2-α kinase 3 (PERK) and interferon-induced, double-stranded RNA-activated protein kinase (PKR; EIF2AK2) reported to be useful for the treatment of cancer, Alzheimer’s disease and immunological disorders.

Gilead Sciences Inc. has identified 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).

Duality Biologics (Suzhou) Co. Ltd. has synthesized trabectedin derivatives reported to be useful for the treatment of cancer.

Boehringer Ingelheim Pharma GmbH & Co. KG has disclosed glutaminyl-peptide cyclotransferase (QPCT; QC) and glutaminyl-peptide cyclotransferase-like protein (QPCTL; IsoQC) inhibitors reported to be useful for the treatment of cancer, fibrosis, atherosclerosis and more.

Aglaeapharma Inc. has described compounds acting as α2-adrenoceptor agonists reported to be useful for the treatment of rhinitis, pain, insomnia, inflammatory disorders, glaucoma, cancer, anesthesia and acute kidney injury, among others.

Anima Biotech Inc. has divulged collagen 1 (COL1) translation inhibitors reported to be useful for the treatment of cirrhosis, fibrosis, nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH), alcoholic fatty liver and autoimmune diseases.

Aligos Therapeutics Inc. has identified programmed cell death 1 (PDCD1; PD-1; CD279)/PD-1 ligand 1 (PD-L1; CD274) interaction inhibitors reported to be useful for the treatment of liver cancer (hepatocellular carcinoma) and hepatitis B (HBV).

Aconcagua Bio Inc. has synthesized calcitonin receptor (CALCR; CT-R) and amylin receptor agonists reported to be useful for the treatment of pain, neurodegeneration, metabolic diseases, bone disease, periodontal disease, metabolic dysfunction-associated steatotic liver disease MASLD), osteogenesis imperfecta and cardiovascular disorders, among others.